DEVASTATED Nadia Sawalha fought back tears in an emotional video as she shared some heartbreaking news. Loose Women star Nadia, 60, struggled to contain her emotions while revealing her best ...

Enhertu is a combination of a chemotherapy drug and targeted therapy. This type of therapy differs from immunotherapy. Doctors prescribe Enhertu for certain types of breast, lung, and other ...

AZ and Daiichi are meanwhile continuing to explore new uses for the drug, and recently started dosing patients in DESTINY-Breast11, a phase III trial of Enhertu in neoadjuvant HER2-positive breast ...

The dosage for Abilify (aripiprazole) may depend on the condition being treated and the form of the drug prescribed. Other factors, including your age and how you respond to treatment, may affect ...

Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful 'improvement' in the DESTINY-Gastric04 Phase III trial, regarding the primary endpoint of ...

Enhertu significantly improves overall survival in HER2-positive metastatic gastric cancer compared to ramucirumab and paclitaxel. DESTINY-Gastric04 is the first phase 3 trial showing Enhertu's ...

Credit: SewCreamStudio / Shutterstock. Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful ‘improvement’ in the DESTINY-Gastric04 Phase III trial, ...

Cambridge: AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a randomized clinical trial in second-line metastatic stomach cancer ...

There is interest in using quercetin for a number of other purposes, but there isn't enough reliable information to say whether it might be helpful. Pregnancy and breast-feeding: There isn't ...

TOKYO & MUNICH - Daiichi Sankyo (TSE: 4568) and AstraZeneca (LON:AZN) (LSE/STO/Nasdaq: NASDAQ:AZN) have announced that their drug ENHERTU (trastuzumab deruxtecan) has been recommended for approval in ...

(Reuters) – The European Union’s health regulator on Friday backed AstraZeneca and Daiichi Sankyo’s drug Enhertu as a breast cancer treatment for patients who received endocrine therapy but are not ...